Tauriga Sciences Inc. Reports Meaningful Progress With Respect to its Ongoing Pharmaceutical Development Efforts
February 18 2020 - 8:04AM
InvestorsHub NewsWire
Tauriga Sciences Inc. Reports
Meaningful Progress With Respect to its Ongoing Pharmaceutical
Development Efforts
NEW YORK, NY -- February 18, 2020 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a revenue generating Company that
operates through the development, distribution, and licensing of
proprietary products as well as the evaluation of potential
acquisition opportunities and equity investments, today reported
meaningful progress in the development of its pharmaceutical grade
version of Tauri-Gum™. On January 13, 2020, the Company
announced the formation of a wholly owned subsidiary, “Tauriga
Pharma Corporation,” to reflect the ongoing development of a
pharmaceutical Nausea Regulation (“Anti-Nausea”)
product. The Company has finalized the formulation for
this proposed pharmaceutical grade version of Tauri-Gum™ and is now
focused on securing Intellectual Property (“IP”) as well as holding
discussion(s) with the Food & Drug Administration (“FDA”).
The Company has retained the law-firm of Lowenstein Sandler (the
“Firm”) to represent it, in connection with regulatory matters
related to this proposed pharmaceutical product
development. The Company is working directly with the
heads of the Firm’s FDA Practice, Chemicals & Life Sciences
Patent Practice, and Life Sciences Group.
The Company will continue to update its shareholders, via press
release(s), should there be further progress and/or material
event(s) – with respect to these pharmaceutical development
efforts.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG)
is a revenue generating Company that operates through the
development, distribution, and licensing of proprietary products as
well as the evaluation of potential acquisition opportunities. One
such opportunity on which the Company has acted, involves the
Company having entered into the cannabidiol (or “CBD”) infused
chewing gum product business, as more fully described above and in
prior press releases. This CBD infused chewing gum product
has been branded under the following name:
Tauri-Gum™. The Company is currently in production of
three distinct flavors of Tauri-Gum™: MINT, BLOOD ORANGE, and
POMEGRANATE. On December 6, 2019 the Company announced
that it completed the initial production run (thereby expanding its
existing product lines) with the introduction of a 25mg Vegan CBD
Isolate Infused vegan gummy (“gum drop”), branded under the name:
Tauri-Gummies™. Further, the Company continues to
identify and evaluate additional potential opportunities to
generate revenue, as well as shareholder value, and leverage its
resources and expertise to build a diversified and sustainable
business model. Please visit our corporate website
at www.tauriga.com.
The Company has also announced the development of a Cannabigerol
(“CBG”) Isolate infused version of Tauri-Gum™. The
flavor that has been selected is Starfruit/Peach and each piece of
gum will contain 10mg of CBG Isolate / Each blister pack will
contain 80mg of CBG Isolate. The Company expects to
commence production during its 4thFiscal Quarter of 2020 (January
1, 2020 – March 31, 2020).
In addition, on March 11, 2019, the Company announced the
official launch of its E-Commerce site - as part of its Tauri-Gum™
commercialization strategy. This site can be accessed by
visiting the following URL address: www.taurigum.com
Pharmaceutical Development: On January 13, 2020, the Company
announced the formation of a wholly owned subsidiary, “Tauriga
Pharma Corporation,” to reflect the ongoing development of a
pharmaceutical Nausea Regulation (“Anti-Nausea”)
product. This proposed product has been conceived as a
pharmaceutical grade version of Tauri-Gum™ (incorporating a
significantly higher concentration of CBD).
The Company has established corporate offices in both New York
City (USA) and Barcelona (Spain).
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due
to known and unknown risks and uncertainties, such as are not
guarantees of general economic and business conditions, the ability
to successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other filings made from time to time with the Securities and
Exchange Commission. Such forward-looking statements are made only
as of the date of this release, and Tauriga assumes no obligation
to update forward-looking statements to reflect subsequent events
or circumstances. You should not place undue reliance on these
forward-looking statements.
There can be no guarantee that the Company will ultimately be
successful, in developing any type of Pharmaceutical
product(s).
Contact:
CONTACT INFORMATION
Tauriga Sciences, Inc.
555 Madison Avenue, 5th Floor
New York, NY 10022
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Attachment
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2024 to May 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From May 2023 to May 2024